Published in J Addict Med on August 05, 2014
Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Int J Drug Policy (2015) 0.88
Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders. J Subst Abuse Treat (2016) 0.75
Willingness to Receive Treatment for Hepatitis C among Injecting Drug Users on Methadone Program: Implications for Education and Treatment. Addict Health (2016) 0.75
Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. Addict Disord Their Treat (2017) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med (2006) 18.63
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet (2011) 6.21
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int (2011) 3.36
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology (2012) 2.59
Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med (2005) 1.97
Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis (2008) 1.86
Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend (2007) 1.64
Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend (2001) 1.62
Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis (2006) 1.61
Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis (2005) 1.36
Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis (2005) 1.35
The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol (2012) 1.26
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis (2012) 1.20
Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can J Gastroenterol (2011) 1.18
Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Serv Res (2007) 1.18
Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treat (2005) 1.16
Knowledge of hepatitis among active drug injectors at a syringe exchange program. J Subst Abuse Treat (2005) 1.07
Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug Alcohol Rev (2012) 1.03
Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat (2010) 0.99
Offers of hepatitis C care do not lead to treatment. J Urban Health (2007) 0.98
Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States. J Subst Abuse Treat (2011) 0.96
Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States. J Addict Dis (2011) 0.95
Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review. Clin Gastroenterol Hepatol (2013) 0.94
Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol (2013) 0.93
Increasing public awareness about hepatitis C: development and validation of the brief hepatitis C knowledge scale. Scand J Caring Sci (2009) 0.89
Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults. J Viral Hepat (2013) 0.89
HIV and HCV health beliefs in an inner-city community. J Viral Hepat (2010) 0.88
Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs. Drug Alcohol Depend (2011) 0.84
Knowledge about Hepatitis-C among methadone maintenance treatment patients in Israel. Subst Use Misuse (2010) 0.81
Impact of monetary incentives on adherence to referral for screening chest x-rays after syringe exchange-based tuberculin skin testing. J Urban Health (2003) 0.81
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80
Increases in Drug and Opioid Overdose Deaths - United States, 2000-2014. MMWR Morb Mortal Wkly Rep (2016) 3.72
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int (2011) 3.36
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology (2008) 2.81
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 2.49
Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med (2013) 2.46
Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis (2010) 1.96
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol (2007) 1.74
Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood (2007) 1.72
Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep (2015) 1.69
HCV screening practices and prevalence in an MCO, 2000-2007. Am J Manag Care (2011) 1.51
HIV/hepatitis C virus-coinfected patients with normal alanine aminotransferase levels. J Acquir Immune Defic Syndr (2006) 1.44
Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis (2009) 1.36
Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood (2003) 1.33
Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis (2005) 1.31
Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr (2007) 1.30
Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs. Public Health Rep (2007) 1.29
Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem (2008) 1.22
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis (2012) 1.20
Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. J Immunol (2003) 1.19
The New York policy on smoking in addiction treatment: findings after 1 year. Am J Public Health (2012) 1.19
Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis (2003) 1.18
Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol (2011) 1.18
The scope and mechanism of phosphonium-mediated S(N)Ar reactions in heterocyclic amides and ureas. J Org Chem (2007) 1.16
Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis (2012) 1.14
CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. J Infect Dis (2011) 1.12
Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis (2005) 1.12
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology (2012) 1.09
Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 1.07
Low rates of hepatitis screening and vaccination of HIV-infected MSM in HIV clinics. Sex Transm Dis (2012) 1.05
Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis (2013) 1.00
A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther (2008) 1.00
Centers for Disease Control and Prevention initiatives to prevent hepatitis C virus infection: a selective update. Clin Infect Dis (2012) 0.99
Telaprevir-based treatment effects on hepatitis C virus in liver and blood. Hepatology (2014) 0.99
Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemma. AIDS Patient Care STDS (2009) 0.98
Models of community-based hepatitis B surface antigen screening programs in the U.S. and their estimated outcomes and costs. Public Health Rep (2011) 0.97
"To share or not to share?" Serosorting by hepatitis C status in the sharing of drug injection equipment among NHBS-IDU2 participants. J Infect Dis (2013) 0.96
Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States. J Subst Abuse Treat (2011) 0.96
Identification and Linkage to Care of HCV-Infected Persons in Five Health Centers - Philadelphia, Pennsylvania, 2012-2014. MMWR Morb Mortal Wkly Rep (2015) 0.95
Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States. J Addict Dis (2011) 0.95
Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr (2004) 0.95
The Program Evaluation and Monitoring System: a key source of data for monitoring evidence-based HIV prevention program processes and outcomes. AIDS Educ Prev (2006) 0.94
Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol (2013) 0.93
Noninjection drug use: an under-appreciated risk factor for hepatitis C virus transmission. Liver Int (2008) 0.93
Taxonomy for strengthening the identification of core elements for evidence-based behavioral interventions for HIV/AIDS prevention. Health Educ Res (2011) 0.92
Noninvasive markers of hepatic fibrosis: are they ready for prime time in the management of HIV/HCV co-infected patients? J Hepatol (2005) 0.89
Disparities in Health Services for HIV/AIDS, Hepatitis C Virus, and Sexually Transmitted Infections: Role of Substance Abuse Treatment Programs. J Addict Med (2009) 0.87
Substance abuse treatment clinician opinions and infectious disease service delivery. J Addict Dis (2009) 0.86
Changing treatment paradigms: hepatitis C virus in HIV-infected patients. AIDS Patient Care STDS (2007) 0.85
Reduced sexual risk behaviors among people living with HIV: Results from the Healthy Relationships Outcome Monitoring Project. AIDS Behav (2011) 0.85
Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. Am J Public Health (2012) 0.84
Unique and differential protein signatures within the mononuclear cells of HIV-1 and HCV mono-infected and co-infected patients. Clin Proteomics (2012) 0.83
More rare birds, and the occasional swan. Gastroenterology (2009) 0.83
Hepatitis C virus in human immunodeficiency virus-infected individuals: an emerging comorbidity with significant implications. Semin Liver Dis (2003) 0.82
Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients. J Hepatol (2010) 0.82
County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States. J Acquir Immune Defic Syndr (2016) 0.81
IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients. J Acquir Immune Defic Syndr (2013) 0.81
Data to guide the "test and treat era" of hepatitis C. Gastroenterology (2012) 0.81
Dideoxynucleoside analogues should be used cautiously in patients with hepatic steatosis. Clin Infect Dis (2006) 0.81
Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy. PLoS One (2013) 0.81
Electronic health information system at an opioid treatment programme: roadblocks to implementation. J Eval Clin Pract (2011) 0.81
Direct oxa-Pictet-Spengler cyclization to the natural (3a,5)-trans-stereochemistry in the syntheses of (+)-7-deoxyfrenolicin B and (+)-7-deoxykalafungin. J Org Chem (2009) 0.81
Understanding the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection. Clin Liver Dis (2007) 0.80
Liver-to-plasma vaniprevir (MK-7009) concentration ratios in HCV-infected patients. Antivir Ther (2015) 0.80
Physician nonadherence with a hepatitis C screening program. Qual Manag Health Care (2013) 0.80
Depression and fatigue in chronic hepatitis C patients with and without HIV co-infection. Psychosomatics (2013) 0.79
An Electronic Health Record-based Intervention to Promote Hepatitis C Virus Testing Among Adults Born Between 1945 and 1965: A Cluster-randomized Trial. Med Care (2017) 0.79
Identification of substance use and dependence among patients with viral hepatitis. Dig Liver Dis (2010) 0.78
C-5 substituted heteroaryl-3-pyridinecarbonitriles as PKCtheta inhibitors: part II. Bioorg Med Chem Lett (2009) 0.78
Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein. Liver Int (2004) 0.78
A multidisciplinary approach to identify a degradation product in a pharmaceutical dosage form. J Pharm Biomed Anal (2010) 0.78
Characteristics of Fentanyl Overdose - Massachusetts, 2014-2016. MMWR Morb Mortal Wkly Rep (2017) 0.77
Editorial commentary: Management of hepatitis C Virus in HIV-infected patients in the era of direct-acting antivirals. Clin Infect Dis (2013) 0.77
Chemical interactions between an active pharmaceutical ingredient and its counterion in a tromethamine salt under forced degradation conditions. Drug Dev Ind Pharm (2011) 0.77
Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment. J Subst Abuse Treat (2012) 0.77
Safety, efficacy, and tolerability of nelfinavir-containing antiretroviral therapy for patients coinfected with HIV and hepatitis C undergoing methadone maintenance. J Subst Abuse Treat (2006) 0.77
Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational Intervention. J Addict Med (2016) 0.76
Evaluation of an electronic medical record system at an opioid agonist treatment program. J Addict Med (2014) 0.75
Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa. J Hepatol (2010) 0.75
FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B. BMC Gastroenterol (2014) 0.75
Hepatitis C virus testing of persons born during 1945-1965. In response. Ann Intern Med (2013) 0.75
Electronic medical record system at an opioid agonist treatment programme: study design, pre-implementation results and post-implementation trends. J Eval Clin Pract (2011) 0.75
News from the CDC: Translating science into HCV infection screening recommendations. Transl Behav Med (2011) 0.75
Quality of care in patients with chronic hepatitis C virus infection. Ann Intern Med (2011) 0.75
Substance abuse treatment as HIV prevention: more questions than answers. J Natl Med Assoc (2010) 0.75
Acute and chronic diarrhea. Postgrad Med (1994) 0.75